CONFIDENTIAL

1

Investor Presentation

Exhibit 99.1

CONFIDENTIAL

2

Safe Harbor Statement

This

presentation

may

contain

statements

that

are

not

historical

facts

and

are

considered

“forward-looking”

within

the

meaning

of

the

Private Securities Litigation Reform Act of 1995.  These forward-looking statements are identified by their use of the terms: “expect(s),”

“intend(s),”

“may,”

“plan(s),”

“should,”

“could,”

“will,”

“believe(s),”

“anticipate(s),”

“estimate(s),”

or similar terms.  Oracle Healthcare

Acquisition

Corp.

(“Oracle”

or

the

“Company”),

Precision Therapeutics, Inc. (“PTI”) or their respective representatives may also make

similar forward-looking statements from time to time orally or in writing.  You are cautioned that these forward-looking statements are

subject to a number of risks, uncertainties, or other factors that may cause (and in some cases have caused) actual results to differ

materially from those described in the forward-looking statements.  These risks and uncertainties include, but are not limited to, the

following: the risk that the merger transaction described in this presentation may not be consummated in a timely manner, if at all; the

inability

to

obtain

the

required

vote

for

approval

of

the

Company’s

stockholders

in

order

to

consummate

the

merger;

the

outcome

of

any

legal

proceeding

instituted

against

the

Company

and/or

others

in

connection

with

the

proposed

merger;

the

failure

of

the

conditions

to

the

consummation of the merger to be satisfied; the termination of the merger agreement prior to the consummation of the merger; the

businesses of the Company or PTI suffering as a result of uncertainty surrounding the merger, including, but not limited to, potential

difficulties

in

employee

retention,

adverse

effects

on

client

or

customer

relationships

and

disruption

of

current

plans

or

operations,

or,

if

the

merger

agreement

is

terminated

or

the

merger

otherwise

fails

to

occur,

the

uncertainties

associated

with

any

anticipated,

potential

or

actual subsequent transaction involving the Company or any liquidation of the Company; the diversion of the attention of the Company’s

and/or PTI’s

management from ongoing business operations; the enactment or imposition of future regulatory or legislative actions that

adversely affect the Company, PTI or any industry or jurisdiction in which any of them operates its business; the adverse effects of other

economic, business and/or competitive factors; and other risks detailed in the Company’s current filings with the Securities and Exchange

Commission,

including,

without

limitation,

its

most

recent

filings

on

Form

10-K

or

Form

10-Q,

which

discuss

these

and

other

important

risk

factors concerning the Company’s operations.   These factors may not constitute all factors that could cause actual results to differ

materially from those discussed in any forward-looking statement.  Oracle and PTI operate in continually changing business environments

and

new

factors

emerge

from

time

to

time.

The

Company

cannot

predict

such

factors

nor

can

it

assess

the

impact,

if

any,

of

such

factors

on

its

or

PTI’s

financial

position

or

their

respective

results

of

operations

or

whether

or

when

the

merger

will

be

consummated. 

Accordingly, forward-looking statements should not be relied upon as a predictor of actual results.  Many of the factors that will determine

the Company’s future results or whether or when the merger will be consummated are beyond its ability to control or predict.  In light of

the significant uncertainties inherent in the forward-looking statements contained herein, you should not rely on forward-looking

statements.  Additional factors that may affect the future results of Oracle and/or PTI are set forth in the Company’s filings with the

Securities

and

Exchange

Commission,

which

are

available

via

the

Internet

at

www.sec.gov.

Neither Oracle, PTI nor any of their

respective

representatives

undertakes

any

obligation

to

publicly

update

or

revise

any

forward-looking

statements,

whether

as

a

result

of

new information, future events or otherwise the otherwise.

CONFIDENTIAL

3

Precision Therapeutics, Inc.

We are a personalized medicine company dedicated to assisting physicians in

optimizing cancer therapy for their patients

The Challenge

Less than one in four patients benefits from chemotherapy

Responses are inconsistent from one patient to another

Physicians are faced with an increasing number of options

Ineffective therapies dramatically impact patients’

lives and prognoses

Our Solution

ChemoFx —

A proprietary test that shows a patient’s likely response to

different therapies using their own tumor cells and drugs selected by their

doctor

Actionable results that can help break therapeutic ties

Positive impacts on patients, physicians, and payors

CONFIDENTIAL

4

Company Highlights

Breakthrough technology platform

Significant market opportunity

Strong clinical validation

Clear revenue growth path

Experienced management team

CONFIDENTIAL

5

ChemoFx

CONFIDENTIAL

6

Chemotherapy Involves Costly Choices

Physicians are faced with an increasing number of options

Response to chemotherapy is inconsistent from one patient to another

Ineffective therapies dramatically impact patients’

lives and prognoses

Costs of chemotherapy are substantial

Example: Recurrent Ovarian

19 treatments acceptable for use in recurrent ovarian cancer*

*Guidelines of the National Comprehensive Cancer Network (NCCN)

Response to Carboplatin

No response to Gemcitabine

No response to Carboplatin

Response to Doxil

CONFIDENTIAL

7

ChemoFx Helps Select Optimal Therapy

Utilizes patients’

own living tumor cells from surgery or

biopsy; integrates the effects of protein, genes, and

unknown factors

Test is available for solid tumor types

Tests drugs or combinations selected by the physician on

the malignant cells

Leads to more informed choices and better patient

outcomes

Drug A

Drug B

Drug C

CONFIDENTIAL

8

ChemoFx Process

Isolate and Enrich Tumor Cell Population

Challenge Cells with Chemotherapy

Control Well

Enumerate Surviving Cells

Treated Well

Sample Dose Curve

Interpret Results

0      1      2      3      4      5      6      7      8      9

10

Doses

1.25

1.00

0.75

0.50

0.25

0.00

CONFIDENTIAL

9

Different Patients Respond Differently

Multiple Patients’

Response Curves

0

1

2

3

4

5

6

7

8

9

10

0.00

0.25

0.50

0.75

1.00

1.25

Doses

Gemcitabine

CONFIDENTIAL

10

Personalized and Actionable Results

Straight-forward

information for physicians

CONFIDENTIAL

11

ChemoFx Predicts Patient Response

5 studies completed –

Total n of 450

Patients treated with a drug reported as responsive experienced a median progression-free

interval approximately 3 times longer

than patients treated with a drug reported as non-

responsive.

Current Clinical Evidence

Source: International Journal of Gynecologic Cancer (Jan–Feb 2006)

Ovarian Cancer

Non-responsive

Intermediate

Responsive

0

5

10

15

20

25

30

Progression Free Interval (months)

CONFIDENTIAL

12

Gallion et al; Int

J

Gynecol

Cancer 2006

135 patient subset of 256 ovarian and peritoneal cancer patients

Approximately 3X longer PFI for patients treated with drugs classified

as

responsive

vs.

non-responsive

(p<0.01)

Heinzman, et al;

Pathology 2007

Cell culture process produced average increase in malignant cell

population of 37% (p<0.0001)

All 50 specimen resulted in

60% malignant cells (p=0.01)

Ness R.B. et al;

AntiCancer

Research

2002

64% patients predicted to have a response achieved a response

100% patients predicted to have no response did not respond

21 specimens

Nickles

Fader; ASCO

abstract 2005

84 primary ovarian cancer patients

Platinum sensitive women had nearly 3X longer PFI than patients

treated with drugs classified as non-responsive

(p<0.007)

Biopsy Feasibility (2)

ChemoFx can be performed on small biopsy specimens

14 and 25 specimens

Current Clinical Evidence

CONFIDENTIAL

13

Proprietary method to isolate and enrich tumor cell population;

30–50x less tissue required

Proprietary in vitro method to encompass therapeutically

relevant dose range

Proprietary process directly counts each cell (versus indirect metabolic,

cell growth, or other markers and statistical averages)

Proprietary method categorizes tumor as sensitive or resistant to each

drug or regimen

Strong IP on ChemoFx Through 2026

7 patents issued and 8 patents pending

Process Step

Protection

Isolate Tumor Cells

Treat with Drugs

Count Surviving Cells

Interpret the Results

CONFIDENTIAL

14

We offer ChemoFx at a list price of $450 per drug or combo

Average invoiced price is approximately $3,300

Medicare

Prospectively pays for gynecologic cancers upon initial claim submission,

since 2Q06

Commercial reimbursement

Over 425 private payors have paid on a case-by-case basis

Reimbursement: A Success Story

CONFIDENTIAL

15

Making a Long Sought-After Solution Viable

Clinical Utility

Measures sensitivity and resistance

Increases successful outcomes for patients

Economic Value

Reduces costs to healthcare system

Clinical Validation

Validated in clinical studies

Commercial Viability

Automated and scaleable

Small tumor size requirement

Attributes

Earlier Generation

Tests

ChemoFx 

CONFIDENTIAL

16

Market

CONFIDENTIAL

17

Solid tumor cancers treated with chemotherapy in which:

Multiple standards of care exist, or no standard exists

Choice

of

chemotherapy

regimen

is

not

clear-

common

situation

in

metastatic, recurrent cancers

Broad Market Opportunity

Average $3,300 billed/test

Ovarian market

$250 million

All four >

$3 billion

(dollars in millions)

Annual Market Opportunity

Recurrent

Late-stage

Ovarian

Breast

Colorectal

Lung

$2,000

$1,500

$1,000

$500

$0

ChemoFx has been used in over

30 different types of cancer

CONFIDENTIAL

18

Strategy

CONFIDENTIAL

19

Establishing ChemoFx as a Standard of Care

Drive market adoption via direct sales

Demonstrate value in clinical studies

Invest in technology to enhance product offering

Achieve broad-based coverage from payors

Corporate Strategy

CONFIDENTIAL

20

Initial sales focus on

gynecologic oncologists

Establish presence within

hospitals

Develop relationships with

pathology and operating room

staffs

Expand presence in additional

tumor types by leveraging

process strengths in hospitals

Drive Market Adoption via Direct Sales

450

400

350

300

250

200

150

100

50

0

20

18

16

14

12

10

8

6

4

2

0

Billed Tests

Sales Reps

Sales Force

Established

450

400

350

300

250

200

150

100

50

0

20

18

16

14

12

10

8

6

4

2

0

Billed Tests

Sales Reps

1Q06

2Q06

3Q06

3Q07

2Q07

1Q07

4Q06

450

400

350

300

250

200

150

100

50

0

20

18

16

14

12

10

8

6

4

2

0

Billed Tests

Sales Reps

400

350

300

250

200

150

100

50

0

20

18

16

14

12

10

8

6

4

2

0

Billed Tests

Sales Reps

1Q06

2Q06

3Q06

3Q07

2Q07

1Q07

4Q06

CONFIDENTIAL

21

Clinical Studies Strategy

Expand into additional tumor types

Partner with large cooperative groups

US Oncology, NSABP, Yale University, U.S. Department of Defense

Launch additional investigator initiated studies

Studies in Progress

Four studies in ovarian and breast cancers

Observational Study (The Registry)

Track actual clinical performance in the field and mine information for future

product development

Demonstrate Value in Clinical Studies

CONFIDENTIAL

22

Ovarian cancer

prospective trial:

PT-301

Yale and various other sites

Progression-free survival and response endpoints

Physicians blinded to assay results

Breast cancer

prospective trial:

PT-205

Breast cancer

prospective trial:

PT-302

Breast cancer

prospective trial:

PT-304

Observational study

(The Registry)

Clinical Studies in the Field

US

Oncology

Research

-

34

patients

ChemoFx

embedded in clinical trial of new chemotherapy

Show preliminary demonstration of predictive value in breast cancer

NSABP (B-40) -

1200 patients

Neo-adjuvant breast cancer patients, randomized treatment with three

chemotherapies and with or without a biologic agent

Physicians blinded to results of assay

Tumor response endpoint

U.S. Department of Defense and University of Pittsburgh Cancer

Institute –

224 patients

Physicians blinded to the results of the assay

Ongoing study collecting clinical outcomes on commercial specimens

from participating physicians

CONFIDENTIAL

23

Additional

Chemos

ChemoFx

Targeted Therapies/Biologics

Genomic Markers

Invest in Technology to Enhance Product Offering

Extending the ChemoFx Platform

>30

Tumor

Types

CONFIDENTIAL

24

Achieve Broad-based Coverage from Payors

First Medicare appeals victory

Secured PPO contracts at favorable rates

Reimbursed by >100 payors on a case-by-

case basis

Second Medicare

appeals victory

Secured favorable

Medicare price

Prospective Medicare coverage

(gynecologic cancers)

>425 payors reimbursed on case-

by-case basis

Addition of reimbursement directors

Increase sophistication of billing

and appeals process

Invest in managed care infrastructure

2003

2004

2005

2006

2007–2010

Build affirmative commercial policies

in gynecologic cancers

Initiate process for new indications

Increase coverage

CONFIDENTIAL

25

Regulatory Environment

Regulatory Situation

PTI Plan

Potential FDA regulation

Transition period provided

Long

Term

Short

Term

Leverage assets and opportunities

Clinical studies already in field

Future regulation is a barrier to entry

Regulated by CLIA

Process tests from all

50 states

Prepare for regulation

Internal controls

Clinical studies

CONFIDENTIAL

26

Sean McDonald

President and CEO

17 years experience leading

healthcare companies. Founder of

Automated Healthcare and Group

President of McKesson Automation

Group

David Heilman

CFO

27 Years of financial experience with

GNC Corp. and First Westinghouse

Capital Corporation

Sharon Kim

V.P., Business Development

17 years in business development

and healthcare consulting at

McKesson and Deloitte Consulting

Michael Gabrin

CTO/C/O

21 years in technology and product

development, Vocollect, Inc.,

Westinghouse

Matthew Marshall

V.P., Sales and Marketing

22 years of sales experience at

McKesson, Automated Healthcare,

HBO & Company

Holly Gallion, M.D.

V.P., Clinical Affairs

24 years in gynecologic oncology at

Magee-Women’s Hospital/University

of Pittsburgh and University of

Kentucky

Perry Dimas

V.P., Payor Relations

10 years of securing reimbursement

for proprietary diagnostic products

including Cytyc and XDX

Alan Wells, M.D., D.M.

CSO

16 years in Pathology at University of

Pittsburgh and University of Alabama

at Birmingham

Management Team

CONFIDENTIAL

27

Board of Directors

Joel Adams

PTI Director since 2003

Founder, President and Managing

General Partner of Adams Capital

Management, Inc., a venture capital

Firm

Larry Feinberg

Chairman, Oracle Director since

2005

Founder and Managing General

Partner of Oracle Partners, L.P.;

Pres. of Oracle Investment

Management

Kevin Johnson

PTI and Oracle Director since 2005

Former CEO, President, and

Chairman of DIANON Systems,

Inc.; Chairman of Aureon

Laboratories Inc.; Director of

MDdatacor, Inc.; Advisory board

member of New Leaf Venture

Partners

Rich Kollender

PTI Director since 2006

Principal and partner of Quaker

BioVentures; C.P.A. and Member of

American and Pennsylvania

Institutes of Certified Public

Accountants

Stan Lapidus

Chairman, PTI Director since 2001

Founder and CEO of Helicos

BioSciences

Corporation; Founder

and former President of EXACT

Sciences Corporation and Cytyc

Corporation

Joel Liffmann

President, COO, Oracle Director

since 2005

Principal of Oracle Investment

Management; Member of Oracle

Strategic Capital, LLC.

Per Lofberg

Oracle Director since 2005

President and CEO of Merck Capital

Ventures, LLC; Former President and

Chairman of Merck-Medco Managed

Care, LLC; Director of Cytel, Inc.;

Director of Ventiv

Health, Inc.; Director of

PHT, Inc.; Director of ImpactRx, Inc.

Sean McDonald

President, CEO and

PTI Director since 2001

Director of Respironics, Inc.; Founder of

Automated Healthcare and Group

President of McKesson Automation

Group

Ken Weisshaar

PTI Director since 2007

Board member of Orthofix

International

N.V.; Former director of Digene

Corporation.  Former COO and Strategy

Advisor for Sensatex, Inc.; Former CFO

of Becton Dickinson & Co.

CONFIDENTIAL

28

Financial Overview &

Valuation

CONFIDENTIAL

29

Attractive Financial Model

Significant revenue growth

Attractive gross margins

Strong operating leverage

Not capital intensive

Transaction Summary

CONFIDENTIAL

30

Summary of Historical Financials

139

137

171

226

243

Depreciation……………….……………..

Years ended December 31,

Nine months ended

September 30,

2006

2007

2004

2005

2006

(unaudited)

(unaudited)

(In thousands, except for numbers of tests and per test amounts)

Number of tests billed………………………….

406

285

483

260

977

Average net revenue per test billed

…….....

$776

$891

$1,064

$896

$1,672

Net revenues from tests billed………………...

$315

$254

$514

$233

$1,634

Reversals of Medicare claim denials…………

1,234

1,666

332

161

37

Net revenues

1,549

1,920

846

394

1,671

Laboratory Costs………………………...

984

978

1,078

735

1,327

Gross Profit

……………………………………

565

942

(232)

(341)

344

Gross Margin…………………………….

36%

49%

-27%

-87%

21%

Operating expenses:

Sales and marketing…………………….

$307

$376

$1,801

$999

$3,607

Research and development…………….

3,003

2,814

4,682

3,179

3,576

General and administrative……………..

2,752

2,282

2,452

1,521

2,729

Net losses from Operations

…………………

$(5,740)

$(4,756)

$(9,338)

$(6,177)

$(9,707)

CONFIDENTIAL

31

PTI Projected Revenue ($ Millions)

(1)

Projected Financials for PTI

(1)

Projections utilized the following assumptions:

Increase in ovarian market penetration from 5% to 30%

Increase in aggregate reimbursement rate for all classes of payors from

approximately 40% to 75%

Continuing growth of number of tests based upon expansion of Sales and

Marketing efforts in line with historical experience

40

30

20

10

0

-10

-20

-30

-40

(32.9)

32.4

7.9

(20.9)

PTI Projected EBITDA ($ Millions)

(1)

40

30

20

10

0

-10

-20

-30

-40

2008

2009

2010

2011

140

120

100

80

60

40

20

0

40.9

121.8

140

120

100

80

60

40

20

0

40.9

2011

2010

2009

2008

113% CAGR

12.6

83.6

CONFIDENTIAL

32

September 30, 2007

Assuming

Maximum

Approval

(1)

Assuming

Minimum

Approval

(2)

(In thousands)

Cash and cash equivalents……………………................

$132,386

$108,987

Working capital…………………………………................

126,322

102,923

Total assets………………………………………..............

137,946

114,547

Long-term obligations (less current portion)…………….

3,339

3,339

Total liabilities………………………………………………

10,834

10,834

Stockholders’

equity……………………………………….

127,112

103,713

Selected Pro Forma Condensed

Combined Balance Sheet Data

(1)

Assumes that no Oracle stockholders convert their shares of Oracle common stock into their pro rata share

of the amount held in the trust account.

(2)

Assumes that 19.99% of the issued and outstanding shares of Oracle common stock were voted against

the merger and that the holders of such shares of Oracle common stock properly elected to convert such

shares of common stock into a pro rata share of the amount held in the trust account.

CONFIDENTIAL

33

OHAC is a special purpose acquisition corporation (SPAC) formed in

September 2005

March 8, 2006: Raised $113.5M (net) in its IPO

–

15M units (1 common share + 1 warrant @ $6.00/share)

–

3.75M common shares and 833,334 warrants held by founders

November 30, 2007: Held $120.2M in trust

January 4, 2008:

Share price: $7.90

Warrant price: $0.63

Unit price: $8.46

PTI is a life sciences company developing and commercializing tests

intended to assist physicians individualize cancer therapy

December 3, 2007: OHAC signs a merger agreement with PTI

Shareholder vote scheduled for no later than March 8, 2008

Oracle

Healthcare

Acquisition

Corporation

(“OHAC”)

Transaction Summary

Precision

Therapeutics

Background

on the

Merger

CONFIDENTIAL

34

Offering Summary

19.0M shares of Oracle common stock issued for all outstanding PTI shares

4.6M

shares

reserved

for

issuance

upon

exercising

of

outstanding

warrants

and options

4.25M upon achievement of one of the following after the closing:

Trailing 12 month net revenues of at least $7M from the sale of services

or products for use in connection with non-gynecological cancers

Trailing

12

month

net

revenues

of

al

least

$40M

from

the

sale

of

services

or products for any use

Cumulative

aggregate

net

revenues

of

at

least

$10M

from

the

sale

of

services or products for use in connection with non-gynecologic cancers

If market price is

less than

$7.78 per share 180 days after the closing, Oracle

either issues or reserves up to 6,666,667 shares for issuance

Prior to March 9

Base

Consideration

Milestone

Consideration

Top-up

Closing

CONFIDENTIAL

35

Transaction Terms

Date of Definitive Agreement: December 3, 2007

Market Capitalization: Pro forma capitalization will include:

PTI Transaction Value:

Conditions to Close:

Shareholder approval: less than 20% of Oracle stockholders requesting

redemption

Customary closing conditions for transactions of this nature

(1)

Current Oracle shares outstanding does not include outstanding warrants

(2)

Shares

issued

to

PTI

does

not

include

milestone

payment

of

4.25M

shares

and

top-up

consideration

of

up

to

6.67M shares

$334,565,000

=

$7.90

X

42,350,000

=

4,600,000

+

19,000,000

+

18,750,000

Post Merger

Market

Capitalization

Oracle Share

Price

(1/4/2008)

Post Merger Fully-

Diluted

Shares Outstanding

Shares

Reserved for

PTI Options

and Warrants

Shares Issued

for PTI Common

Stock

(2)

Current

Oracle

Shares

Outstanding 

186,440,000

=

$7.90

X

23,600,000

Total PTI

Transaction

Equity Value

Oracle Share

Price

(1/4/2008)

Total Oracle

Shares

Issued /

Reserved

(2)

(1)

CONFIDENTIAL

36

Rationale for Oracle Healthcare-PTI Merger

PTI operates in large and growing markets with significant opportunities

for accelerated expansion

ChemoFx can be an important tool in selecting the proper

chemotherapy

Well capitalized PTI will be better positioned to compete in the

rapidly

emerging personalized medicine space

Public stock provides currency for acquisitions/partnerships as well as for

incentivizing employees

Abilities and experience of the directors of Oracle will be highly valuable

in executing business strategy

CONFIDENTIAL

37

Pro Forma Ownership

Note:

PTI ownership consists of 19.0M shares; does not

include milestone payment of 4.25M shares, top-up

consideration of 6.67M shares, and 4.6M shares

reserved for PTI options and warrants

Note:

PTI ownership consists of 23.6M shares; does not

include milestone payment of 4.25M shares and top-up

consideration of up to 6.67M shares

Oracle shares includes exercise of 15.0M warrants

SPAC Founders Shares includes exercise of 0.834M

warrants

PTI Common

Shareholders

50.4%

Oracle Public

Shareholders

39.7%

SPAC Founders Shares

9.9%

PTI Common

Shareholders

40.5%

Oracle Public

Shareholders

51.6%

SPAC Founders Shares

7.9%

Assuming No Exercise of

Oracle or PTI Warrants

Assuming Full Exercise of

Oracle or PTI Warrants

CONFIDENTIAL

38

Over the last two years, the Molecular Diagnostics

Composite Index meaningfully outperformed the broader

markets

2yr. Relative Price Performance

80

100

120

140

160

180

200

220

240

260

280

1/5/2006

3/5/2006

5/5/2006

7/5/2006

9/5/2006

11/5/2006

1/5/2007

3/5/2007

5/5/2007

7/5/2007

9/5/2007

11/5/2007

% Change

Genomic Health Inc.

122.3%

Molecular Diagnostics Comp Index (CPHD, CRA, GHDX, GPRO, MGRM, MYGN, NSPH, TWTI)

57.2%

S&P 500 Index

9.8%

CONFIDENTIAL

39

Company Highlights

Breakthrough technology platform

Significant market opportunity

Strong clinical validation

Clear revenue growth path

Experienced management team